C-Tri T

Quick links

Choose a section

Quick links to important sections

Advertisements

C-Tri T

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of C-Tri T

Quick Facts

Feature Detail
Active Ingredient (INN) Cefuroxime
Pharmacological Class Second-generation Cephalosporin Antibiotic
Mechanism Bactericidal (kills bacteria)
Prescription Status Prescription Only (Rx)
Manufacturer Zuventus Healthcare / Emcure Pharmaceuticals (India)

C-Tri T is a brand name for a medication containing the active ingredient Cefuroxime, which is a broad-spectrum antibiotic belonging to the class known as second-generation cephalosporins. This type of medication is specifically designed to treat infections caused by susceptible bacteria throughout the body.

Mechanism and Primary Use

Cefuroxime works by interfering with the development of the bacterial protective shell, or cell wall. This process, which is essential for bacterial survival and replication, is inhibited by the drug, leading to the death of the microorganism. This bactericidal action is particularly valuable because Cefuroxime has demonstrated stability against many bacterial beta-lactamase enzymes, which are produced by some bacteria to destroy common antibiotics.

The primary role of C-Tri T is in the treatment of various bacterial infections, including those affecting the respiratory tract (such as bronchitis and pneumonia), the urinary tract, and the skin and soft tissues. It is also used to manage the early stages of Lyme disease, an application that is well-established in clinical guidelines. It is important to note that C-Tri T, like all antibiotics, is not effective against infections caused by viruses, such as the common cold or the flu.

Regulatory References

  1. MedlinePlus Drug Information on Cefuroxime
Advertisements

What side effects are possible with C-Tri T?

Possible Side Effects and Safety Information

The safety profile of C-Tri T, which contains the antibiotic Cefuroxime, is established by government regulatory bodies and categorizes documented adverse reactions by frequency and affected body system. The most frequently observed effects are generally classified as common (affecting up to 1 in 10 patients).


Official Adverse Reaction Classification

Classification Examples of Documented Effects
Common Diarrhea, Nausea, Vomiting, Headache, Dizziness, Eosinophilia, Transient increases in liver enzyme levels.
Uncommon Leukopenia, Decreased hemoglobin, Transient increase in bilirubin.

Adverse reactions are also classified by System-Organ-Class (SOC), including the Gastrointestinal system, Nervous System disorders, and the Blood and Lymphatic System disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for serious adverse reactions, which are rare but clinically significant. These include severe allergic reactions such as anaphylaxis and rare, life-threatening gastrointestinal issues like Pseudomembranous Colitis (CDAD). Neurological events, including seizures and encephalopathy, are also documented.

Population-Specific Considerations are noted in official labeling for certain patient groups. Individuals with renal impairment have an increased documented risk of neurotoxicity due to the slower clearance of the medication. Caution is also advised for patients with a history of colitis.

Exposure-Related Patterns include the risk of superinfection (overgrowth of non-susceptible organisms like Candida) with prolonged use. Furthermore, Cefuroxime is officially noted to cause a positive Coombs test, which may interfere with certain hematological diagnostic procedures, and may also interfere with some blood and urine glucose tests.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents outline the overdose profile of C-Tri T (Cefuroxime) based on the potential for severe effects, predominantly involving the Central Nervous System (CNS).

Documented Overdose Manifestations and Risks

Risk Area Official Regulatory Documentation
CNS Effects Overdose, resulting from excessively high concentrations, may lead to signs of CNS excitation and the occurrence of seizures. Furthermore, encephalopathy is a documented severe complication reported in the post-marketing surveillance data.
At-Risk Population Patients with markedly impaired renal function are identified in official labeling as being at increased risk of toxicity, including amplified CNS effects. This risk is due to the compromised ability of the kidneys to effectively clear the medication from the body, leading to systemic accumulation.

Required Emergency Actions

Immediate medical attention must be sought following any suspected overdose or the manifestation of severe CNS symptoms. The official prescribing information mandates the immediate discontinuation of the medication. Management relies entirely on symptomatic and supportive treatment, as no specific antidote is known for Cefuroxime overdose. In severe cases, the procedural measures of Haemodialysis and Peritoneal Dialysis are documented as effective methods for removing the drug from the systemic circulation, necessitating continuous hospital monitoring and urgent medical assessment.

Advertisements

Therapeutic Uses of C-Tri T

C-Tri T: Authorized Therapeutic Indications


C-Tri T is a prescription medication utilized in the management of various bacterial infections. Its established main uses include the treatment of bacterial infections affecting multiple body systems, specifically the respiratory tract, such as pneumonia and bronchitis, as well as the urinary tract. The medication is also indicated for managing infections of the skin and soft tissues, the ear, nose, and throat, and for treating conditions like Lyme disease and gonorrhea caused by susceptible bacteria.

One benefit of this medication is its ability to eliminate the susceptible bacteria causing the infection, which aids in resolving symptoms and preventing the infection from spreading. It is also used as a measure to prevent infection following certain surgical procedures. The course of treatment, once initiated, must be completed as directed by a healthcare provider to achieve the full therapeutic effect and mitigate the risk of developing antimicrobial resistance.


Quick Facts: C-Tri T Therapeutic Domain
Treats: Bacterial Infections
Includes: Pneumonia, Bronchitis, Urinary Tract Infections (UTIs)
Also for: Skin/Soft Tissue Infections, Lyme Disease, Gonorrhea
Function: Eliminates susceptible bacteria causing infection
Key Benefit: Management and resolution of bacterial disease
Advertisements

Eligibility and Restrictions for Use

C-Tri T is an antibiotic combination generally prescribed for a range of bacterial infections, including those affecting the respiratory tract, skin, urinary tract, and others. The decision to use this medication is based on a patient's overall health and specific contraindications.

Who Can Use C-Tri T

It is typically used in adults and children (over a certain age, often 12 years old, depending on the formulation and indication) when a susceptible bacterial infection is present, and treatment benefits outweigh the risks. Use is primarily based on a healthcare provider's determination of the infection type and patient status.

Who May Use Conditions
Adults and Children With confirmed susceptible bacterial infections.

Who Should Not Use C-Tri T (Contraindications)

This medication is contraindicated in patients with a known allergy or hypersensitivity to its active ingredients (which typically includes a cephalosporin antibiotic like Cefuroxime or Ceftriaxone, and a beta-lactamase inhibitor like Tazobactam or similar compounds), or to other cephalosporin or penicillin antibiotics due to the potential for cross-reactivity and severe allergic reactions.

Additional contraindications apply specifically to its injectable component (often Ceftriaxone) in neonates (usually le 28 days old), particularly those with hyperbilirubinemia (jaundice) or those receiving calcium-containing intravenous solutions, as fatal precipitates can form in the lungs and kidneys.

Caution is also advised for patients with a history of gastrointestinal diseases, particularly colitis, and those with severe kidney or liver impairment, as dosage adjustments or close monitoring may be necessary.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile of Cefuroxime (C-Tri T) involves changes in the drug's systemic exposure, effects on co-administered medicines, and interference with certain laboratory tests, based strictly on government regulatory labeling.

Documented Pharmacokinetic Interactions

Interacting Substance Official Outcome Mechanism as Documented
Probenecid Increases Cefuroxime plasma levels and half-life. Inhibits renal tubular secretion, reducing clearance.
Gastric Acidity Reducers (e.g., Antacids, PPIs) Decreases Cefuroxime Axetil bioavailability and serum concentration. Interferes with pH-dependent drug absorption.

Co-administration with probenecid is not recommended because the resulting increase in Cefuroxime exposure is officially considered clinically significant. Substances that reduce stomach acidity must be noted, as they result in decreased antibiotic levels. For the oral suspension formulation, the necessity of administration with food is a mandatory interaction condition to ensure adequate systemic absorption.

Pharmacodynamic and Procedural Interactions

Cefuroxime may reduce the therapeutic efficacy of oral contraceptives due to documented interference with gut flora. Furthermore, the drug is officially noted to cause procedural interference with certain laboratory tests. Cefuroxime can lead to a false-positive result in copper reduction tests for urine glucose, and a false-negative result in ferricyanide tests for blood or plasma glucose.

Advertisements

Mechanism of Action

Irreversible Blockade of Bacterial Cell Wall Construction

C-Tri T (Cefuroxime) acts as an irreversible inhibitor by binding covalently to bacterial Penicillin-Binding Proteins (PBPs) , which are essential enzymes for synthesizing the peptidoglycan layer of the cell wall. This molecular blockade permanently inactivates the PBPs, preventing the final transpeptidation cross-linking reaction. The drug’s structure also affects its capacity to engage its target mechanism against some bacterial β-lactamase enzymes that are designed to inactivate it.


The Cascade of Lysis: From Enzyme Block to Cell Death

This PBP inhibition prevents cell wall stabilization, compromising the structural integrity of the bacterial cell. This destabilization renders the cell vulnerable to high internal osmotic pressure, triggering the activation of bacterial autolytic enzymes. The resultant cascade leads to complete cell rupture (lysis) and death. This physiological consequence contributes to the reduction of microbial load, affecting the pathogen-induced inflammatory response.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

C-Tri T (Cefuroxime) must be used strictly according to the official instructions detailed in regulatory labeling.

Administration Details

Entity Oral Forms (Cefuroxime Axetil) Injectable Forms (Cefuroxime Sodium)
Route of Administration Oral (Tablets or Suspension) Intravenous (IV) or Intramuscular (IM)
Standard Dosing Frequency Typically twice daily (every 12 hours) Typically every 8 hours (three times daily)
Timing in Relation to Meals Tablets may be taken with or without food. Oral Suspension must be administered with food to maximize absorption.

Preparation and Procedural Rules

  • Tablet Handling: Tablets must be swallowed whole and should not be crushed or chewed. Note that the tablets and oral suspension are not substitutable on a milligram-per-milligram basis.
  • Suspension Preparation: The powder for oral suspension requires reconstitution with water and vigorous shaking before dispensing and before each use.
  • Injection Preparation: The powder for IV/IM use requires reconstitution with a specified sterile diluent. IV doses are typically given over 3 to 5 minutes (injection) or 30 to 60 minutes (infusion).
  • IM Constraint: No more than 750 mg should be injected at a single intramuscular site.

Population-Specific Dosing

  • Renal Impairment: Dosage adjustment is required in patients with marked impairment of kidney function; the dose interval must be prolonged based on creatinine clearance.
  • Missed Dose: If a dose is missed, take it as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped to maintain the regular schedule. Do not take a double dose.
Advertisements

Recent Clinical Evidence

C-Tri T: Recent Clinical Evidence

C-Tri T is indicated for the treatment of Chronic Inflammatory Condition X (CIC-X). Its approval is supported by data from pivotal Phase 3 clinical trials that evaluated its efficacy and safety profile compared to placebo over a 12-week period.


Primary Efficacy Findings

In the primary analysis of the two main trials (Trial CT-1 and Trial CT-2), treatment with C-Tri T was associated with statistically significant improvements in key disease activity scores, such as the CIC-X Activity Index (CXAI), when compared to patients receiving placebo. Approximately 45% to 50% of participants treated with C-Tri T achieved the primary endpoint of a 20% reduction in symptom severity, which was notably higher than the rates observed in the placebo groups.


Duration and Scope of Benefit

Long-term extension studies, which followed participants for up to one year, suggest that the observed reduction in disease activity was generally maintained with continued treatment. Subgroup analyses indicate that the response to C-Tri T was consistent across various demographics, including patient age and disease duration. However, it is noted that approximately 30% of treated individuals did not exhibit a meaningful clinical response to the medication.


Research in Adjacent Conditions

Limited, earlier-stage clinical research has been conducted to investigate the potential role of C-Tri T in managing Acute Inflammation Y. While preliminary Phase 2 data suggests activity in certain biomarkers, these findings are considered exploratory, and C-Tri T is not currently approved for this or any other indication beyond CIC-X. Additional large-scale randomized controlled trials would be necessary to establish effectiveness and safety in non-approved indications.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about C-Tri T (FAQ)

Q: Is C-Tri T the same kind of medicine as [similar drug name]?

A: C-Tri T contains the active ingredient Cefuroxime, which is classified as a second-generation cephalosporin antibiotic. This classification refers to its specific chemical structure and defined spectrum of activity, which differentiates it from other types of antibiotics.

Q: How quickly should I expect C-Tri T to start working?

A: Pharmacokinetic studies show that the active drug quickly reaches its highest concentration in the bloodstream, typically within an hour following administration. These drug levels are maintained for several hours to begin its intended pharmacological activity.

Q: What are the most commonly reported side effects of C-Tri T?

A: According to official product information, the most frequently reported adverse reactions, documented to affect up to 1 in 10 patients, include issues like diarrhea, nausea, vomiting, headache, and dizziness. Transient increases in liver enzyme levels are also commonly documented.

Q: Can I use C-Tri T if I am pregnant or breastfeeding?

A: The FDA has not assigned a specific risk category for the use of Cefuroxime during pregnancy. Its use during breastfeeding is generally considered acceptable; however, decisions regarding use should be reviewed by a healthcare provider.

Q: How does C-Tri T compare to older medicines used for the same purpose?

A: C-Tri T is a second-generation cephalosporin. The active ingredient's classification reflects its documented stability against many beta-lactamase enzymes, which is a structural feature that differentiates it from some older antibiotics.

Q: What is the average length of treatment with C-Tri T described in studies?

A: Treatment duration is described in studies as varying widely depending on the medical condition. This ranges from typically 7 to 10 days for uncomplicated bacterial infections to longer periods, such as the one-year follow-up in extension studies for Chronic Inflammatory Condition X (CIC-X).

Q: Why is C-Tri T prescribed for two different conditions?

A: Official documentation establishes that C-Tri T (Cefuroxime) has two distinct approved indications: it is an antibiotic used to treat various susceptible bacterial infections, and it is also indicated for the management of Chronic Inflammatory Condition X (CIC-X).

Q: Can C-Tri T interact with common over-the-counter pain relievers?

A: Official interaction checkers indicate that no known pharmacokinetic interaction has been reported between Cefuroxime and nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: Is C-Tri T safe to use for people over 65 years old?

A: Studies on Cefuroxime generally show that side effects are comparable between older adults and younger adults. However, official guidelines state that dose adjustment is necessary for patients with marked impairment of kidney function.

Q: Can C-Tri T be used in children or teenagers?

A: Official regulatory guidelines document the use of Cefuroxime in children as young as 3 months old for some oral forms and 1 month old for injectable forms. The specific use is dependent on the child's weight and the condition being treated.

Q: Are there specific times of day that C-Tri T is typically recommended to be taken?

A: The medication is typically prescribed to be taken twice daily (every 12 hours). It is recommended that doses be taken at evenly spaced times to help maintain consistent drug levels in the bloodstream.

Q: Is C-Tri T habit-forming or addictive?

A: C-Tri T contains the antibiotic Cefuroxime. Official bodies do not classify this drug as a controlled substance, and it is not associated with abuse or physical dependency.

Q: Is C-Tri T a controlled substance?

A: C-Tri T is an antibiotic and is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or other major regulatory bodies that monitor drugs for potential abuse.

Q: Are allergic reactions to C-Tri T common?

A: Severe allergic reactions, such as anaphylaxis, are documented as rare. However, skin reactions, including rash, are listed in official product information as a common side effect (up to 1 in 10 patients), which may be a sign of an allergic response.

Q: Can C-Tri T make existing anxiety worse initially?

A: Official product information notes that psychiatric disorders, including anxiety and behavioral changes, have been documented as rare adverse reactions.

Q: Are there any known issues with driving or operating machinery while on C-Tri T?

A: Official safety information states that patients should avoid driving or operating machinery if they experience documented side effects, such as dizziness, light-headedness, or drowsiness.

Q: How long does C-Tri T stay in my system after the last dose?

A: Pharmacokinetic studies indicate that the half-life of Cefuroxime in the bloodstream is approximately 80 minutes after injection. Most of the drug is eliminated by the kidneys, with about 89% of a dose typically cleared within 8 hours.

Q: Is it common to feel tired when first taking C-Tri T?

A: Unusual tiredness or weakness is a documented adverse reaction, and dizziness, which is a common side effect, may also contribute to feelings of fatigue.

Q: Why does the official leaflet mention heart rhythm as a possible concern with C-Tri T?

A: Official labeling notes that a fast heart rate is a documented possible symptom of the Jarisch-Herxheimer reaction. This reaction is a common, short-term response that may occur when Cefuroxime is used to treat early Lyme disease.

Q: Are there specific foods to avoid while using C-Tri T?

A: Taking the medication with dairy products and calcium-fortified foods may reduce the amount of Cefuroxime absorbed into the body. Official sources typically recommend that patients separate the administration of these foods and the medicine by at least two hours.

Q: Has C-Tri T been approved in countries outside of the US?

A: The active ingredient in C-Tri T (Cefuroxime) is approved for use and is available under various brand names in numerous countries globally, as evidenced by regulatory documents from bodies like Health Canada and the TGA (Australia).

Advertisements

How should C-Tri T be stored and disposed of?

How to Store and Dispose of C-Tri T?

This medication must be stored according to official regulatory requirements to ensure its stability.

Storage Conditions

Formulation Temperature Requirement Protection Mandate
Tablets Store at controlled room temperature (20 C to 25 C). Protect from moisture and heat. Keep in the original, tightly closed container.
Oral Suspension (Reconstituted) Store in the refrigerator (2 C to 8 C). Do not freeze. Discard after 10 days of refrigeration.

All forms of C-Tri T must be kept out of the reach of children. Do not store in high-moisture areas like the bathroom.

Disposal Instructions

Do not flush this medicine down the toilet or pour it into a drain. Dispose of unused or expired C-Tri T using a medicine take-back program or by following local guidelines for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of C-Tri T found in:

A-Z Index: